Abstract: This study aimed to perform a comprehensive meta-analysis of topiramate-augmentation therapy in patients with schizophrenia receiving antipsychotic agents. Data published up to June 20, 2016 were obtained from the PubMed, PsycINFO, and Cochrane Library databases. Twelve randomized controlled trials comparing topiramate to placebo or antipsychotic only were included (n=676 patients). The primary outcome was change in overall symptoms. Relative risk (RR) and standardized mean difference (SMD), along with 95% confidence intervals, were calculated using random effects model for each outcome. Topiramate-augmentation therapy was superior to the control for decreasing overall symptoms (SMD −0.55, 95% confidence interval −0.86 to −0.24; P=0.001; I 2 =55%, eight comparisons, n=380), positive symptoms (SMD −0.4), negative symptoms (SMD −0.47), and Positive and Negative Syndrome Scale general subscale scores (SMD −0.67). Furthermore, topiramate-augmentation therapy decreased weight (SMD −0.69) and body mass index (SMD −0.95) compared with the control. Topiramate was similar to the control with respect to discontinuation due to all causes (RR 1.19), inefficacy (RR 1.71), and adverse events (RR 1.09). Topiramate was associated with higher incidence of paresthesia (RR 2.67) and attention difficulty (RR 8.97) compared with the control. Our results seemed to suggest that topiramate-augmentation therapy improves the psychopathology of schizophrenia with good tolerability and has the additional advantage of weight maintenance. However, because there were some limitations (numbers of studies and patients included in the meta-analysis were small, some studies used completer analysis, Chinese studies were included in the meta-analysis, and studies that had a risk of bias were included in the meta-analysis) in this study, we cannot apply the results of this study in daily clinical practice.
Introduction
Schizophrenia is characterized by positive symptoms, such as hallucinations and delusions, negative symptoms, such as abulia and autism, and cognitive impairments.
A recent network meta-analysis comparing 15 antipsychotics to placebo found that anti psychotics were superior for reducing overall symptoms of schizophrenia. 7 However, all individual effect sizes were moderate, with the exception of clozapine, which had a large effect size compared with placebo. 7 On the other hand, olanzapine and clozapine have been demonstrated to have a higher risk of metabolic abnormalities compared with other second-generation antipsychotics. 8 For example, olanzapine revealed a higher risk of weight gain compared with amisulpride, aripiprazole, asenapine, lurasidone, paliperidone, and risperidone. 8 Risperidone was also associated with the need for more use of antiparkinsonian medication compared with clozapine, olanzapine, quetiapine, and ziprasidone. 9 When comparing antipsychotics (regarding overall symptoms as efficacy, and weight gain as safety), because the effect size of efficacy is smaller than that of safety, such as weight gain, several guidelines for the management of schizophrenia have recommended that the safer antipsychotic should be used for patients with schizophrenia. 10 However, not all patients with schizophrenia respond to the safer antipsychotics.
Topiramate is approved for the treatment of epilepsy and prophylaxis of migraine by the US Food and Drug Administration. 11 A previous review suggested that topiramate effects on psychopathology may be mediated through glutamatergic neurons, especially those expressing kainic acid and α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptors, and by inhibition of nitric oxide production. 12 Although the mechanisms for improving metabolic disturbances are unclear, a previous report demonstrated that topiramate enhances insulin action and glucose transport in adipose cells from obese and insulin-resistant rodents. 13 Further, appetite suppression through hypothalamic AMPA-receptor antagonism is thought to contribute to weight loss. 14 To our knowledge, 12 randomized controlled trials (RCTs) of topiramate have been conducted for the treatment of schizophrenia and related psychoses. [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] There were inconsistent results among these RCTs, however, regarding psychopathology and metabolic outcomes. Although four studies 15, 19, 21, 25 reported that topiramate was superior to control in improving psychopathological outcomes, six studies [16] [17] [18] 20, 23, 26 reported that topiramate was similar to the control in this aspect, and the remaining studies 22, 24 did not report any psychopathological outcomes. To date, two meta-analyses have evaluated topiramate for the treatment of schizophrenia. 27 , 28 Sommer et al 27 reviewed three RCTs, 15, 20, 23 and reported that topiramate augmentation for clozapine showed trend-level improvement regarding overall symptoms compared with placebo. Mizuno et al 28 conducted a metaanalysis of multiple pharmacological strategies to combat weight gain in antipsychotic-treated schizophrenia patients that included two RCTs 19, 21 of topiramate augmentation. The pooled result showed that topiramate significantly lowered weight compared with the placebo (mean difference −5.20 kg). 28 However, these meta-analyses focused on topiramate augmentation as a strategy only for psychopathology or metabolic adverse events (including weight gain), and the number of topiramate trials included was small. In this updated systematic review and meta-analysis of topiramateaugmentation therapy for patients with schizophrenia and its related disorders, we have incorporated all relevant findings involving various antipsychotics from the 12 published RCTs. [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] Because a meta-analysis can increase the statistical power for group comparisons and overcome the limitation of sample size when larger trials are lacking (http://www. cochrane.org), a systematic review and meta-analysis is considered to provide the "best evidence" for clinical practice. Moreover, safety outcomes are critical for adherence; therefore, we also evaluated topiramate-discontinuation rates and individual adverse events.
Materials and methods
Inclusion criteria, search strategy, data extraction, and outcomes This meta-analysis was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. 29 We performed a systematic literature review according to the PICO (patients, intervention, comparison, outcome) strategy: patients, schizophrenia and schizophrenia-related disorders; intervention, topiramate in addition to an antipsychotic agent; comparison, versus placebo in addition to an antipsychotic agent or antipsychotic only; and outcome, primary outcome (improvement in overall symptoms) and secondary outcomes (improvement in positive and negative symptoms and Positive and Negative Syndrome Scale [PANSS] general subscale scores, 30 decreasing weight and body mass index [BMI] , improvement in Clinical Global Impression -Severity [CGI-S], 31 and depressive symptoms, discontinuation rate, and individual adverse events). Only those RCTs involving the use of topiramate in patients with schizophrenia and its related disorders were included.
Relevant studies were identified through searches of PubMed, the Cochrane Library, and PsycINFO citations. There were no language restrictions, and we accepted studies retrieved using the keywords "topiramate" and "schizophrenia" published up to June 20, 2016 . Additional eligible studies were sought by scrutiny of the reference lists from primary articles and relevant reviews. Two authors (YO and KO) checked the inclusion and exclusion criteria for each of the identified studies, and resolved discrepancies in coding by discussion. The same authors independently extracted, checked, and entered data into RevMan version 5.3 for Windows (Cochrane Collaboration, London, UK). When data required for the meta-analysis were missing, the first/corresponding authors were contacted for additional information. We also assessed the risk of bias in the trials using the Cochrane risk-of-bias criteria (domains of randomsequence generation, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting, and other sources of bias) (http://www. cochrane.org).
Data synthesis
The primary efficacy measure was overall symptom reduction as measured by PANSS total scores and Brief Psychiatric Rating Scale (BPRS) 32 total scores ( (Table 1) , and discontinuation rates due to 8) all causes, 9) inefficacy, and 10) adverse events.
In addition, we pooled the data for individual adverse events. With regard to tolerability, discontinuations due to worsening mental condition and unsatisfactory response 17, 23 were considered "discontinuation due to inefficacy", and discontinuation due to low leukocyte levels 23 was considered "discontinuation due to adverse events". For estimation of missing data from individual studies, we imputed the standard deviation (SD) of BPRS-change scores from baseline to end point in Ko et al, 19 from the data of Muscatello et al, 20 and SD of CGI-S and BMI-change scores from baseline to 
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Okuyama et al were accepted (Figure 1 ). Mean study duration was 13.4 (range 8-24) weeks, and 676 patients were included (schizophrenia 579, schizoaffective disorder 48, psychosis and unipolar or bipolar disorder 49). Patient numbers in each treatment arm were 358 for topiramate and 318 for control (consisting of 258 placebo-treated and 60 treatment as usual). The mean number of patients included in the individual studies was 56. Three studies were published in Chinese. [24] [25] [26] We evaluated the methodological quality of the individual studies based on Cochrane risk-of-bias criteria (Figures S1 and S2). Three studies did not employ a placebo control. 18, 24, 25 One study was a crossover design. 23 Seven studies used a completer analysis. [19] [20] [21] [22] [24] [25] [26] Five studies were at high risk of selective reporting bias. 15, 18, 20, 21, 24 One study was sponsored by the pharmaceutical industry. 15 The characteristics of the studies are summarized in Table 2 .
Meta-analysis Efficacy
Topiramate as augmentation to antipsychotic therapy was superior to control (antipsychotic alone or placebo plus antipsychotic) for the reduction of overall symptoms (SMD −0.55, end point in the study of Ko et al 19 from the SD of Chengappa et al. 17 We converted weights from pounds to kilograms for Chengappa et al. 17 We assumed that the number of patients required for evaluating efficacy outcomes in Behdani et al 16 was the same as the number of patients required for evaluating safety outcomes and the number of patients required for evaluating efficacy outcomes in Afshar et al 15 was the same number of randomized patients for each treatment arm, because the trial used general linear model analysis. We used those estimations to increase sample size for analysis to gain as much statistical power as possible. The median highest topiramate dose for all studies except Ko et al 19 was 238 mg/day, so data from the 200 mg/day topiramate group but not the 100 mg/day topiramate group were used for meta-analysis. For individual adverse events, we considered memory disturbances 23 and forgetfulness 17 as "memory loss", and sedation 17, 23 and drowsiness 16 as "somnolence".
statistical analysis
We based our data analyses on intention to treat, observed cases, and crossover studies. This meta-analysis was performed using RevMan. To combine studies, we used the random-effect model described by DerSimonian and Laird. 37 We used this conservative model to address the possibility that underlying effects differed across studies and populations were heterogeneous. For continuous data, we used standardized mean difference (SMD), combining effect size (Hedges' g) data and 95% confidence interval (CI). For dichotomous data, relative risk (RR) was estimated along with the 95% CI. When the random-effect model revealed significant between-group differences in dichotomous outcomes, the number needed to harm (NNH) was calculated. Study heterogeneity was measured using χ 2 and I 2 statistics, with values of P,0.05 and I 2 $50% indicating heterogeneity. 38 In cases where I 2 values were $50% for primary outcome, sensitivity analyses were performed to determine the reasons for heterogeneity. Finally, funnel plots were visually inspected to explore the possibility of publication bias.
Results

study characteristics
Searches of the PubMed, Cochrane Library, and PsycINFO databases yielded 116 hits. We excluded eight duplicate studies, 81 studies based on title or abstract review, and 20 studies after full-text reading. Five additional articles 17, 22, [24] [25] [26] were identified by manually searching the review articles. 17, 39 Finally, 12 eligible studies 
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TOP (100) . (Figure 2A ). Visual inspection of the funnel plot for primary outcome did not suggest publication bias ( Figure S3 
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Sensitivity/subgroup analysis
There was significant heterogeneity in overall symptoms among studies (I 2 =55%, P=0.03), so we performed 13 sensitivity analyses for primary outcome (antipsychotic class, blinding, analyzed population, region, control, study duration, topiramate dose, publication year, diagnosis, number of patients, patient status, language, and sponsorship) ( Table 3 ). Significant heterogeneity in overall symptoms among the 
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Topiramate for schizophrenia various-antipsychotic subgroup, open-label subgroup, Europe-US subgroup, and older publication year (before 2008) subgroup disappeared without significant difference when comparing topiramate to control. On the other hand, significant heterogeneity in the olanzapine subgroup, non-intention-totreat population subgroup, Asia subgroup, the long-duration subgroup (13 weeks or more), low-dose topiramate subgroup (200 mg/day or less), newer publication year (after 2008) subgroup, diagnosis (schizophrenia) subgroup, not treatmentrefractory subgroup, and large number of patients (more than 55) subgroup disappeared when comparing topiramate to control. One study was unique, because it was the only study that was sponsored by the pharmaceutical industry (Table 3) . Figure 4C ) than the controls, it was associated with a higher incidence of paresthesia (RR 2.67, 95% CI 1.15-6.19; P=0.02; I 2 =0, NNH not significant, four comparisons, n=248) ( Figure 5A ) and attention difficulty (RR 8.97, 95% CI 1.17-68.63; P=0.03; I 2 =0, NNH 8, two comparisons, n=120) ( Figure 5B ) than the controls. There were no significant differences in individual adverse events reported (asthenia, constipation, diarrhea, dizziness, dry mouth, fatigue, headache, insomnia, memory loss, muscle weakness, nausea, psychomotor slowing, psychosis exacerbation, or somnolence) between topiramate and control (Table 4) .
Discussion
To the best of our knowledge, the current study is the largest comprehensive systematic review and meta-analysis of topiramate-augmentation therapy for schizophrenia and related diseases. Topiramate augmentation was more efficacious than control (antipsychotic alone or antipsychotic plus placebo) for reducing overall, positive, and negative symptoms, PANSS general subscale scores, weight, and BMI. We did not find any cause for the heterogeneity among individual studies, despite performing 13 sensitivity analyses of overall symptoms. Based on the results of the sensitivity analyses, low-dose topiramate (#200 mg/day)-augmentation therapy for olanzapine may be useful. The prevalence of metabolic syndrome is at least twice as high in schizophrenia patients compared with the age-adjusted population. 40 Given the importance of maintaining medication adherence for schizophrenia, it is often necessary to use a safer but less efficacious antipsychotic. Augmentation therapy should be considered before changing from the safer antipsychotic to one with greater potential efficacy but also higher metabolic risk. 41, 42 In a prospective study, 27% of patients with schizophrenia 
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Okuyama et al eventually developed poor adherence. 43 Moritz et al 44 studied the reasons for antipsychotic nonadherence, and concluded that side effects were the most common reason. Weight gain is also a well-known side effect, especially with secondgeneration antipsychotics, which are more widely used throughout the world than first-generation antipsychotics for treating schizophrenia. 45 Furthermore, augmentation therapy for clozapine may be particularly important, since clozapine is thought to be the final option for treatment-resistant schizophrenia (alongside modified electroconvulsive therapy). If clozapine efficacy is still insufficient, effective augmentation drugs should be considered. 27 However, we cannot apply the results of this study in daily clinical practice because of the following. There are some limitations to this meta-analysis. The main limitation is the paucity of RCTs, despite updating from previous metaanalyses. 27, 28 All the trials included were small, and it is well documented that small trials exaggerate effects. Second, although we utilized a funnel plot to assess potential publication bias, these are generally used only if ten or more studies are included. The third limitation is the short follow-up period (8-24 weeks). Fourth, we did not investigate the optimal topiramate dose for augmentation therapy. Future research should investigate the long-term efficacy of multiple doses and generate more safety data using larger samples. Fifth, although several of our included studies were from China, it has been reported that many Chinese studies are problematic. 46 Some studies included in the meta-analysis did not report detailed information about sequence generation or allocation concealment. Moreover, seven studies used a completer analysis.
Conclusion
Our results indicate that topiramate-augmentation therapy is well tolerated, can improve the psychopathology of schizophrenia, and reduces weight gain associated with antipsychotics. Since there were some limitations in this study, we could not apply the results of this study in daily clinical practice. Future research should investigate long-term efficacy and generate more safety data for schizophrenia patients receiving topiramate augmentation of antipsychotics. 
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Okuyama et al Figure S1 Risk-of-bias summary.
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